Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRd Consolidation in PET-positive Myeloma (CONPET)
NCT03314636Phase 2Active, not recruiting
- Sponsor
- Oslo University Hospital
- Start
- Mar 2018
- Primary completion
- Nov 2021
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by Oslo University Hospital. Started Mar 2018; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03314636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03314636.